Biotech Values

[DewDiligence]

True to form: Teva, in announcing the unfavorable USSC ruling on an injunction (#msg-100802686), sneaks in a little propaganda vis-à-vis Copaxone characterization:

http://finance.yahoo.com/news/teva-announces-supreme-court-denial-134000735.html

The inability to fully characterize the active ingredients of the product leads many experts to believe that the only way to ensure the safety, efficacy and immunogenicity of any purported generic version of COPAXONE would be through full-scale, placebo-controlled clinical trials with measured clinical endpoints (such as relapse rate) in RRMS patients [emphasis added].

I wonder who those experts are, LOL.